Stephen E. Schachterle
Pfizer
8 Papers
13 Citations
Stephen E. Schachterle is an academic researcher from Pfizer. The author has contributed to research in topics: Population & Medicine. The author has an hindex of 3, co-authored 6 publications. Previous affiliations of Stephen E. Schachterle include City University of New York & Johns Hopkins University.
Chat about Author
Papers
Disparities in influenza mortality and transmission related to sociodemographic factors within Chicago in the pandemic of 1918.
Kyra H. Grantz,Madhura S. Rane,Henrik Salje,Gregory E. Glass,Stephen E. Schachterle,Derek A. T. Cummings +5 more
TL;DR: It is shown that living in census tracts with higher illiteracy rates increased the risk of influenza and pneumonia mortality during the 1918 influenza pandemic in Chicago, and that disparities and their determinants should remain targets of research and control in future pandemics.
162
Short-term malaria reduction by single-dose azithromycin during mass drug administration for trachoma, Tanzania.
Stephen E. Schachterle,Stephen E. Schachterle,George Mtove,Joshua Levens,Emily G. Clemens,Lirong Shi,Amrita Raj,J. Stephen Dumler,Beatriz Munoz,Shelia West,David J. Sullivan +10 more
TL;DR: This drug might be beneficial in areas to which malaria and trachoma are endemic and may help in the treatment of these diseases.
42
Cancer incidence and mortality trends in Asia based on regions and human development index levels: an analyses from GLOBOCAN 2020.
TL;DR: In this paper , the authors investigated the relationship between socioeconomic developments in Asia (determined using HDI levels of countries) and cancer incidence and mortality in these nations, and the difference in data was analyzed based on region and HDI level.
19
An Implementation and Visualization of the Tree-Based Scan Statistic for Safety Event Monitoring in Longitudinal Electronic Health Data
Stephen E. Schachterle,Stephen E. Schachterle,Sharon Hurley,Qing Liu,Kenneth R. Petronis,Andrew Bate +5 more
TL;DR: A parsimonious design that could be the basis of a broadly applicable method for multiple drug and safety event pairs is tested, and potential SDRs related to the circulatory system that may reflect the cardiac risk that was described in the itraconazole product label are identified.
15
Classification and characteristics of on-label and off-label apixaban use in Denmark and Sweden.
Nicklas Vinter,Marie Linder,Morten Andersen,Morten Andersen,Alma B Pedersen,Morten Madsen,Stephen E. Schachterle,Stephen E. Schachterle,Quazi Ataher,Jingping Mo,Søren Paaske Johnsen,Vera Ehrenstein +11 more
TL;DR: To estimate the proportion of apixaban users who received the drug for on‐label indications and characterise the patients using Apixaban for on-label and off-label indications, a large number of patients from across Europe and Asia were recruited.
6